KLK7
KLK7 (kallikrein related peptidase 7, also known as SCCE and PRSS6) is a secreted chymotrypsin-like serine protease of the kallikrein family. It contributes to the breakdown of intercellular cohesive structures in the outer epidermis, which allows skin cells to be shed. Browse Assay Genie's current range of KLK7 research reagents below, or read on for the biology behind the target.
KLK7 is a serine protease with chymotrypsin-like activity. It is specific for amino acid residues with aromatic side chains at the P1 position. It may catalyse the degradation of intercellular cohesive structures in the cornified layer of the skin. This proteolysis precedes desquamation, the continuous shedding of the outermost epidermal layer. In vitro, the enzyme cleaves the insulin A chain after tyrosine 14 and the insulin B chain at several leucine, tyrosine and phenylalanine sites. UniProt also notes that it could play a role in activating precursors of inflammatory cytokines.
The KLK7 gene encodes a member of the kallikrein subfamily within the peptidase S1 family. It is one of fifteen kallikrein subfamily genes found in a cluster on chromosome 19. The protein is secreted. Alternatively spliced transcript variants encoding multiple isoforms have been reported. The mouse and rat orthologues are both named Klk7, so the gene can be studied in common rodent models.
The enzyme was originally named kallikrein 7 (chymotryptic, stratum corneum), hence the alias SCCE (stratum corneum chymotryptic enzyme). PRSS6 is a previous symbol. Many kallikrein genes are cancer biomarkers, and KLK7 is no exception. NCBI Gene reports that the encoded protein may play a role in cancer invasion and metastasis. Increased expression is associated with unfavourable prognosis and progression in several cancers. Polymorphisms in the gene may also contribute to the development of atopic dermatitis. This makes the KLK7 protein relevant to both skin biology and oncology.
KLK7 helps degrade intercellular cohesive structures in the cornified layer, so it is a central protease for studying epidermal shedding.
Increased KLK7 expression is associated with unfavourable prognosis and progression in several cancers, and the protease may contribute to invasion and metastasis.
Polymorphisms in the KLK7 gene may play a role in the development of atopic dermatitis.
KLK7 prefers aromatic P1 residues, cleaves insulin chains and may activate precursors of inflammatory cytokines.
KLK7 is a secreted serine protease with chymotrypsin-like activity. It may degrade intercellular cohesive structures in the cornified layer of the skin, enabling the continuous shedding of cells from the surface. It prefers aromatic residues at P1 and could help activate precursors of inflammatory cytokines.
KLK7 is also called SCCE (stratum corneum chymotryptic enzyme) and PRSS6, and its protein name is kallikrein-7. An earlier gene name was kallikrein 7 (chymotryptic, stratum corneum). Its EC number is 3.4.21.117, and alternative splicing yields multiple isoforms.
NCBI Gene links increased KLK7 expression to unfavourable prognosis and progression in several cancers, and polymorphisms to atopic dermatitis risk. Mouse and rat both have a Klk7 orthologue. Check the datasheet of any product for its validated reactivity.
Other kallikrein-related peptidases and serine proteases from the chromosome 19 kallikrein cluster, many of them cancer biomarkers.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P49862; product specifications from Assay Genie datasheets.